The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
Public ClinicalTrials.gov record NCT00536120. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
Study identification
- NCT ID
- NCT00536120
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Biogen
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- BG00002 (natalizumab) Biological
- keyhole limpet hemocyanin (KLH) Biological
- tetanus diphtheria toxoid vaccine (Td) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- Oct 31, 2009
- Completion
- Nov 30, 2009
- Last update posted
- Feb 14, 2017
2008 – 2009
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site 1 | Fullerton | California | 92835 | — |
| Research Site | Centennial | Colorado | 80112 | — |
| Research site | Farmington Hills | Michigan | 48334 | — |
| Research Site | Patchogue | New York | 11772 | — |
| Research Site 3 | Charlotte | North Carolina | 28207 | — |
| Research Site 5 | Oklahoma City | Oklahoma | 73130 | — |
| Research Site | Franklin | Tennessee | 37064 | — |
| Research Site | Dallas | Texas | 75214 | — |
| Research Site 2 | Seattle | Washington | 98122 | — |
| Research Site 4 | Charleston | West Virginia | 25301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00536120, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 14, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00536120 live on ClinicalTrials.gov.